GLP-1 receptor agonists × body weight & composition

TrialLancet (London, England)2017

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.

Carel W le Roux et al.PubMed ↗Publisher ↗

  • Liraglutidelooks good hereLower weight loss.Randomised, large.

What the trial testedrandomised · 2,254 people · 2017

Randomised vs placebo

Lowered weight loss

−4.30percentage points−4.90 to −3.70

liraglutide vs placebo

As reported

difference −4.3 %, 95% CI −4.90 to −3.70

Who was studied, and how

3,731people in the Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities trial, from 2011
2,254of them with obesity, in this paper

The trial randomly assignedassigned by chance

liraglutide
placebo

Lowered weight loss−4.30

randomised

the abstract, start to end

[6.3]; estimated treatment difference -4.3%, 95% CI -4.9 to -3.7,

← favours treatmentfavours comparator →
could be chance
Weight lossliraglutide vs placebo
−4.3−4.90 to −3.70
GLP-1 receptor agonistsBody weight & composition

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.900.90 without it
← favours treatmentfavours comparator →
this paperthis papermore certainless certain
1 / 6

361 papers cite itlatest 60 shown

2017
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 28237263